Who are Ampicillin + gentamicin or cefotaxime + gentamicin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ampicillin-gentamicin-or-cefotaxime-gentamicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ampicillin + gentamicin or cefotaxime + gentamicin — Competitive Intelligence Brief

Ampicillin + gentamicin or cefotaxime + gentamicin (Ampicillin + gentamicin or cefotaxime + gentamicin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination (beta-lactam + aminoglycoside). Area: Infectious Disease.

phase 3 Antibiotic combination (beta-lactam + aminoglycoside) Bacterial cell wall (beta-lactams) and bacterial ribosome (aminoglycoside) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ampicillin + gentamicin or cefotaxime + gentamicin (Ampicillin + gentamicin or cefotaxime + gentamicin) — PENTA Foundation. This combination regimen uses two or three antibiotics with different mechanisms to provide broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ampicillin + gentamicin or cefotaxime + gentamicin TARGET	Ampicillin + gentamicin or cefotaxime + gentamicin	PENTA Foundation	phase 3	Antibiotic combination (beta-lactam + aminoglycoside)	Bacterial cell wall (beta-lactams) and bacterial ribosome (aminoglycoside)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination (beta-lactam + aminoglycoside) class)

PENTA Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ampicillin + gentamicin or cefotaxime + gentamicin — Competitive Intelligence Brief. https://druglandscape.com/ci/ampicillin-gentamicin-or-cefotaxime-gentamicin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab